# A Study of the ReCor Medical Paradise System in Clinical Hypertension

Study · id `cardio:ct-nct02649426` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02649426](<https://clinicaltrials.gov/study/NCT02649426>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02649426

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 282 participants.

## Technical summary

Registry record NCT02649426. Randomized; triple masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2020-09 (actual). Results posted on 2024-06-28.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 282 participants (enrolled count; ClinicalTrials.gov record NCT02649426, source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)
- Started: 2016-03 (actual) (ClinicalTrials.gov record NCT02649426, source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)
- Primary completion: 2020-09 (actual) (ClinicalTrials.gov record NCT02649426, source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)
- Completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT02649426, source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)
- Results first posted: 2024-06-28 (ClinicalTrials.gov record NCT02649426, source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)
- Countries: United States; Belgium; France; Germany; Netherlands; Poland; United Kingdom (ClinicalTrials.gov record NCT02649426, source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02649426-2026-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the ReCor Medical Paradise System in Clinical Hypertension
- Acronym: RADIANCE-HTN
- Condition: Hypertension
- Condition: Vascular Diseases
- Intervention (Device): The Paradise® Renal Denervation Ultrasound System
- Intervention (Device): Sham Procedure
- Lead sponsor: ReCor Medical, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: ReCor Medical, Inc. (`cardio:org-recor-medical-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial (`cardio:pubmed-34010611`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial (`cardio:pubmed-34433763`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial (`cardio:pubmed-34620570`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial (`cardio:pubmed-36350593`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c1667416bea6586d46d909b2688f285dc49227dcc5300d3bc0a0edd2721ff329
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
